Navigation Links
Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer
Date:3/4/2013

MUMBAI, India, March 4, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink:GATA) announced today they have entered into a multiyear contract with Eskayef Bangladesh LTD., a leading Indian pharmaceutical manufacturer. Under the terms of the agreement Groupe Athena will assist Eskayef in obtaining FDA approval for their Bangladesh manufacturing facility during the first stage, and assist with U.S approval of individual drugs in subsequent stages of the agreement.  The contract could result in a 20% increase to annual revenues beginning fiscal 2014.

Mr. M. Motiar Rehman , General Manager of Eskayef stated the following with regard to the agreement: "We are very pleased to enter into an agreement with Groupe Athena, Inc. for getting our facilities approved by the FDA. We are excited by the prospect of entering the U.S. market and want to focus more resources in the United States once we get our facilities approved. We are hoping for a long and fruitful partnership with Groupe Athena Inc., in fulfilling this objective."

Groupe Athena Chairman, D. Purohit stated, "We are extremely proud to be able to align ourselves with such a dynamic company as Eskayef Bangladesh. Once the facilities are approved by the FDA, Eskayef is planning to become a contract manufacturer and Groupe Athena will be assisting Eskayef in getting their drugs approved and identifying suitable partners in the United States".

The Indian pharmaceutical industry has grown dramatically and was estimated to be over $21 Billion in 2010 with continued double digit annual growth expected through this decade. GATA has emerged as a vital component to this growth by its ability to help Indian manufacturers get their products approved by the FDA for sales in the US. 

The Company believes it has an advantage over competitors due to their facilities being based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment and the purchase of their new testing facility, the company will continue to take on additional contracts and continue to anticipate further growth.

The company is progressing with plans to apply for listing on the NASDAQ Bulletin Board quotation system after the completion of the audit for this fiscal year ending June 30, 2013.

For more information on Groupe Athena, Inc. please go to www.otcmarkets.com/stock/GATA/quote or visit our corporate website at www.groupeathena.com.

About Groupe Athena, Inc.

Groupe Athena Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 17 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com

For more information contact: 
Paul Cornell 
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
2. Groupe Athena, Inc. Reports Record First Quarter Revenues, Adoption Of IFRS Accounting Standard In Anticipation Of Applying For Listing On The NASDAQ Bulletin Board
3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
4. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
5. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
6. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
7. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
8. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
9. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
10. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
11. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):